Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 10, 2013, Pages 1327-1332

  Smith, K ^a,c   Gemmell, C G ^b   Lang, S ^a  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TELAVANCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BIOFILM; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84890569592     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1883-z     Document Type: Article

References (18)

1. Boyce JM, Cookson B, Christiansen K, Hori S, Vuopio-Varkila J, Kocagöz S, Oztop AY, Vandenbroucke-Grauls CM, Harbarth S, Pittet D (2005) Meticillin-resistant Staphylococcus aureus. Lancet Infect Dis 5:653-663
2. Mah TF, O'Toole GA (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9:34-39
3. Gemmell CG (2004) Glycopeptide resistance in Staphylococcus aureus: is it a real threat? J Infect Chemother 10:69-75
4. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673
5. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC (2008) Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46:668-674
6. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF (2008) In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 62:116-121
7. Leuthner KD, Cheung CM, Rybak MJ (2006) Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58:338-343
8. Corey GR, Stryjewski ME, Weyenberg W, Yasothan U, Kirkpatrick P (2009) Telavancin. Nat Rev Drug Discov 8:929-930
9. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48(Suppl 1):5-16
10. Smith K, Perez A, Ramage G, Lappin D, Gemmell CG, Lang S (2008) Biofilm formation by Scottish clinical isolates of Staphylococcus aureus. J Med Microbiol 57:1018-1023
11. Smith K, Perez A, Ramage G, Gemmell CG, Lang S (2008) Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents 33:374-378
12. Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM (2009) Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 53:3375-3383
13. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP (2009) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:1127-1134
14. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG Jr, Morganroth J, Barriere SL, Kitt MM, Corey GR; FAST 2 Investigator Group (2006) Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50:862-867
15. LaPlante KL, Mermel LA (2009) In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother 53:3166-3169
16. Madrigal AG, Basuino L, Chambers HF (2005) Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 49:3163-3165
17. Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS (2006) Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58:462-465
18. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME; ATTAIN Study Group (2011) Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 52(1):31-40